2024-10-10T10:03:38-05:00 2023-12-31 410746749 CLIFTONLARSONALLEN LLP 8215 GREENWAY BOULEVARD SUITE 600 MIDDLETON WI 53562 990 2023-01-01 411426406 MINNEAPOLIS HEART INSTITUTE FOUNDATION MINN 6128633833 920 E 28TH STREET 100 MINNEAPOLIS MN 554071191 CHARLES ZAUGG CHIEF FINANCIAL OFFICER 6128633833 2024-10-04 1 0 KIMBERLY ANDERSON P00188889 6086628600 2024-10-04 2023 2024-10-15 13:58:12Z CHARLES ZAUGG 920 E 28TH STREET 100 MINNEAPOLIS MN 554071191 29569884 0 X WWW.MPLSHEART.ORG X 1982 MN TO IMPROVE THE CARDIOVASCULAR HEALTH OF INDIVIDUALS AND COMMUNITIES THROUGH RESEARCH & EDUCATION. 28 28 136 1624 0 0 17801434 7376505 5409134 5033714 1730486 2334828 -1285114 -408580 23655940 14336467 85045 95308 0 0 9939930 11179969 15702 0 1826046 4767577 5274878 14808254 16550155 8847686 -2213688 71060713 66731497 14935609 10396446 56125104 56335051 X THE MISSION OF THE MINNEAPOLIS HEART INSTITUTE FOUNDATION IS TO IMPROVE THE CARDIOVASCULAR HEALTH OF INDIVIDUALS AND COMMUNITIES THROUGH INNOVATIVE RESEARCH AND EDUCATION. 0 0 10660022 95308 4899904 2023 MHIF RESEARCH ACCOMPLISHMENTS- MHIF RESEARCH WAS SIMULTANEOUSLY PUBLISHED IN THE NEW YORK TIMES AND NEW ENGLAND JOURNAL OF MEDICINE ALONG WITH ITS OPPORTUNITY TO BE ON ONE OF THE LARGEST STAGES FOR CARDIOVASCULAR RESEARCH AT THE 2023 AMERICAN COLLEGE OF CARDIOLOGY. DR. PAUL SORAJJA PRESENTED PRIMARY OUTCOMES FROM THE TRILUMINATE PIVOTAL CLINICAL TRIAL EVALUATING THE TRICLIP (MANUFACTURED BY ABBOTT) FOR TRISCUSPID REGURGITATION. DR. SORAJJA IS THE ROGER L. AND LYNN C. HEADRICK FAMILY CHAIR FOR THE MHIF VALVE SCIENCE CENTER AND NATIONAL PRINCIPAL INVESTIGATOR FOR THE TRILUMINATE PIVOTAL TRIAL. MHIF WAS THE TOP ENROLLER (ENROLLING THE FIRST AND LARGEST NUMBER OF PATIENTS) OF ALL 75 CLINICAL SITES PARTICIPATING IN THIS RESEARCH TRIAL IN THE UNITED STATES, CANADA AND EUROPE. MHIF LED THE WAY AS THE FIRST TO PROVIDE THIS TECHNOLOGY TO A PATIENT AS PART OF EARLY RESEARCH IN 2017 AND COMPLETED THE FIRST-IN-THE-WORLD ENROLLMENT IN THE TRILUMINATE PIVOTAL TRIAL IN SEPTEMBER 2019.- MHIF CONTRIBUTED TO RESEARCH THAT WAS SUBMITTED TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), EARNING APPROVAL OF A NEW TREATMENT FOR PATIENTS LIVING WITH HYPERTENSION. RECOR MEDICAL'S PARADISE ULTRASOUND RENAL DENERVATION IS A FIRST-OF-ITS-KIND ULTRASOUND-BASED RENAL DENERVATION TECHNOLOGY DESIGNED TO LOWER BLOOD PRESSURE BY DENERVATING OVERACTIVE SYMPATHETIC NERVES SURROUNDING THE RENAL ARTERIES. MHIF HAS BEEN INVOLVED IN THE RESEARCH OF THIS TECHNOLOGY SINCE 2016 AND WAS THE HIGHEST ENROLLER OF PATIENTS IN THE U.S. (SECOND HIGHEST IN THE WORLD) OF ALL THE CLINICAL SITES THAT PARTICIPATED IN THE RESEARCH THAT WAS PART OF THE FDA REVIEW.- 350+ NEW PATIENTS ENROLLED IN RESEARCH; 220+ ACTIVE STUDIES WITH 2200+ PATIENTS AT ANY GIVEN TIME- 3,000+ VISITS WITH PATIENTS WHO HAVE HOPE AND OPTIONS THROUGH RESEARCH - 60,000+ DOWNLOADS FROM PHYSICIANS AROUND THE WORLD FOR THE SUITE OF MHIF DIGITAL APPLICATIONS AVAILABLE SHARING EXPERTISE AND CLINICAL INSIGHTS IN HEART VALVE AND CORONARY ARTERY DISEASE - 650+ RECORD HIGH OF PUBLICATIONS, ABSTRACTS, PODIUM PRESENTATIONS AND INVITED TALKS AT INTERNATIONAL CONFERENCES- 8 MHIF INTERNATIONAL SCHOLARS CONTRIBUTED TO ADVANCING RESEARCH; THESE SCHOLARS ARE PRACTICING MEDICAL DOCTORS FROM AROUND THE WORLD WHO COME TO MHIF TO PARTICIPATE IN RESEARCH IN PARTNERSHIP WITH LEADING MHIF RESEARCH PHYSICIANS- FORMED NEW RELATIONSHIPS IN THE COMMUNITY TO CONTRIBUTE TO CHANGE AROUND HEALTH EQUITY AND ACCESS TO CARE- 11,000+ HOURS OF PROFESSIONAL AND COMMUNITY EDUCATION EACH YEAR REACHING 4,000+ ATTENDEES- 6,000 MEMBERS OF THE COMMUNITY GATHERED AT THE MINNEAPOLIS ARMORY TO CELEBRATE THE IMPACT OF LIFESAVING RESEARCH AS PART OF THE ANNUAL HEART360 CONCERT FOR WORLD-CLASS HEART RESEARCH. 457555 0 133810 2023 MHIF EDUCATION HIGHLIGHTSEQUAL TO OUR COMMITMENT TO RESEARCH IS OUR DEDICATION TO SHARE THE LEARNINGS FROM RESEARCH THROUGH EDUCATION, ALLOWING FOR LOCAL, NATIONAL AND INTERNATIONAL IMPACT AS WE CHALLENGE AND ADVANCE THE STANDARD OF CARE FOR ALL PATIENTS. MHIF PROUDLY SHARED THE DETAILS OF OUR RESEARCH THROUGH 650+ PUBLICATIONS, PRESENTATIONS AND ABSTRACTS AT NATIONAL AND INTERNATIONAL CONFERENCES. WE PUBLISHED 264 MANUSCRIPTS IN PEER-REVIEWED JOURNALS, SHARING LEARNINGS FROM WORLD-CLASS CARDIOVASCULAR RESEARCH. WE ALSO OFFERED VARIOUS PUBLIC AND PROFESSIONAL EVENTS (MANY OF WHICH WERE STILL VIRTUAL) TO INCREASE AWARENESS, UNDERSTANDING AND MANAGEMENT OF VARIOUS HEART CONDITIONS. MANY OF OUR EVENTS ATTRACTED PARTICIPANTS FROM AROUND THE WORLD.OUR CARDIOVASCULAR GRAND ROUNDS PROGRAM ENSURES ATTENDEES ARE WELL-VERSED IN THE LATEST RESEARCH OUTCOMES AND EVIDENCE-BASED GUIDELINES. THROUGH 32 SESSIONS FEATURING 53 SPEAKERS, MHIF PROVIDED PROFESSIONAL EDUCATION TO MORE THAN 3,100 HEALTH CARE PROFESSIONALS. THESE ACCREDITED EDUCATION ACTIVITIES PROVIDE PHYSICIANS AND OTHER HEALTH CARE PROVIDERS THE OPPORTUNITY TO REVIEW AND DISCUSS THE LATEST DEVELOPMENTS IN CARDIOVASCULAR CARE EVERY MONDAY MORNING DURING OUR GRAND ROUNDS SEASON (SEPTEMBER MAY).IN 2023, MHIF HOSTED 11 INTERNS FROM AROUND THE COUNTRY WHO CONTRIBUTED TO 11 DIFFERENT GROUNDBREAKING RESEARCH PROJECTS. THANKS TO THE GENEROUS SUPPORT FROM INDIVIDUAL DONORS, MHIF OFFERS AN EXCEPTIONAL CLINICAL RESEARCH INTERNSHIP PROGRAM TAILORED FOR UNDERGRADUATE STUDENTS ASPIRING FOR A CAREER IN MEDICINE OR PURSUING A PRE-MED TRACK. THIS DISTINCTIVE LEARNING OPPORTUNITY INVOLVES MATCHING INTERNS WITH PHYSICIAN MENTORS WHO OVERSEE THE INVESTIGATOR-INITIATATED RESEARCH PROJECTS. OTHER ASPECTS OF THE INTERNSHIP INCLUDE SHADOWING HOSPITAL ROTATIONS, ATTENDING INSIGHTFUL FIELD TRIPS, ENGAGING IN LUNCH-AND-LEARN SESSIONS WITH ALLINA HEALTH MINNEAPOLIS HEART INSTITUTE PHYSICIANS, PRESENTING THEIR RESEARCH FINDINGS AT AN OPEN-HOUSE, POSTER SESSION. NUMEROUS RESEARCH ENDEAVORS CULMINATE IN INTERNS POTENTIALLY CO-AUTHORING ARTICLES PUBLISHED IN RENOWNED SCIENTIFIC JOURNALS. ADDITIONALLY, SELECT INTERNS MAY HAVE THE CHANCE TO SHOWCASE THEIR WORK AT NATIONAL CARDIOVASCULAR CONFERENCES.SINCE THE INCEPTION OF THE INTERNSHIP PROGRAM, 235 CLINICAL RESEARCH INTERNS HAVE CONTRIBUTED TO 223 POSTERS AND PRESENTATIONS AT NATIONAL SCIENTIFIC SESSIONS, 219 PUBLICATIONS IN PEER-REVIEWED JOURNALS, AND 59% OF FORMER INTERNS ARE NOW PRACTICING PHYSICIANS! 11117577 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 1 1 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 53 0 1 136 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 28 28 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC ND OR PA RI SC TN UT VA WV WI DC X X X CHARLES ZAUGG 6128633833 920 E 28TH ST MINNEAPOLIS MN 55407 JEFFREY STEINLE CHAIR 5.00 X X 0 0 0 THOMAS GUNDERSON PAST CHAIR 5.00 X X 0 0 0 GREG GRAVES TREASURER 2.00 X X 0 0 0 BEN BACHE-WIIG MD DIRECTOR 1.00 X 0 0 0 MOSI BENNETT MD DIRECTOR 0.50 X 0 0 0 CRAIG BENTDAHL DIRECTOR 1.00 X 0 0 0 CONLEY BROOKS JR DIRECTOR 1.00 X 0 0 0 JULEEN CHRISTOPHER DIRECTOR 1.00 X 0 0 0 SARA CRIGER DIRECTOR 1.00 X 0 0 0 LARRY GETLIN DIRECTOR 0.25 X 0 0 0 SHARON HAWKINS DIRECTOR 1.00 X 0 0 0 DAVID HURRELL MD DIRECTOR 2.00 X 0 0 0 CAROL HUTTNER DIRECTOR 1.00 X 0 0 0 WILLIAM KATSIYIANNIS MD DIRECTOR 2.00 X 0 0 0 JIM KING DIRECTOR 5.00 X 0 0 0 GINNY KIRBY DIRECTOR 1.00 X 0 0 0 PATRICE KLOSS DIRECTOR 1.50 X 0 0 0 RICHARD MEYER DIRECTOR 2.00 X 0 0 0 LORI MILBRANDT DIRECTOR 6.00 X 0 0 0 MARC NEWELL MD DIRECTOR 5.00 X 0 0 0 MICHAEL PETERSON MD DIRECTOR 1.00 X 0 0 0 CHERI ROLNICK PHD DIRECTOR 1.00 X 0 0 0 RETU SAXENA MD DIRECTOR 1.00 X 0 0 0 SCOTT SHARKEY MD DIRECTOR 12.00 X 0 0 0 JAY TRAVERSE MD DIRECTOR 4.00 X 0 0 0 ARIEL JOHNSON PHD DIRECTOR 1.00 X 0 0 0 BOBBY STEFFEN MD DIRECTOR 1.00 X 0 0 0 BREE WILLIAMSON DIRECTOR 1.00 X 0 0 0 JOSEPH SCHWARTZ DIRECTOR 1.50 X 0 0 0 FRANCES HOFFMAN DIRECTOR 1.00 X 0 0 0 JOSH HOWELL DIRECTOR 2.00 X 0 0 0 KEVIN HARRIS MD DIRECTOR 2.00 X 0 0 0 KRISTIN BOWLDS DIRECTOR 2.00 X 0 0 0 KRISTINE FORTMAN CHIEF EXECUTIVE OFFICER 40.00 X 470269 0 128842 CHARLES ZAUGG CHIEF FINANCIAL OFFICER 40.00 X 199059 0 58631 ROSS GARBERICH VICE PRESIDENT - SCIENTIFIC SERVICES 40.00 X 190519 0 50035 LISA TINDELL VICE PRESIDENT - RESEARCH 40.00 X 212413 0 42588 JESSE HICKS VICE PRESIDENT-ADVANCEMENT 40.00 X 258597 0 48003 TAMARA O'BLACK SENIOR DIRECTOR, QUALITY 40.00 X 193489 0 50489 JANET DICK CHIEF TALENT AND STRATEGY 40.00 X 194576 0 36389 KRISTIN LAMBRECHT PROGRAM DIRECTOR - CIRC 40.00 X 188281 0 54278 BAVANA RANGAN PROGRAM DIRECTOR - CCAD 40.00 X 177679 0 29472 LARISSA STANBERRY DIRECTOR OF DATA SCIENCE 40.00 X 182901 0 25852 2267783 0 524579 25 0 1 0 CLIFTONLARSONALLEN 220 SOUTH 6TH STREET SUITE 300 MINNEAPOLIS MN 55402 AUDIT AND TAX SERVICES 120824 1 10109 432784 6933612 768100 7376505 RESEARCH STUDY REVENUE 541900 4899904 4899904 MISC PROGRAM REVENUE 541900 133810 133810 5033714 1377795 1377795 3740654 11492607 3728620 10547608 12034 944999 957033 957033 548609 432784 957189 -408580 -408580 14336467 5033714 0 1926248 X 14500 14500 80808 80808 1528456 465312 724057 339087 7822012 5896020 1126074 799918 456388 328622 77641 50125 736298 546205 90190 99903 636815 454928 109598 72289 69284 49723 18393 1168 63919 63919 86313 86313 2148553 1569265 487213 92075 6082 100 5982 239576 158801 9493 71282 408975 33533 370951 4491 943122 747524 102941 92657 532893 337923 115974 78996 281779 222804 30399 28576 135775 84100 51675 MISCELLANEOUS AND BAD D 227359 36342 99048 91969 EMPLOYEE SEMINAR FEES 62290 55736 6247 307 EMPLOYEE DUES AND MEMBE 43281 18322 24868 91 EQUIPMENT/MAINTENANCE 21070 16531 2021 2518 4607 478 3535 594 16550155 11117577 3606532 1826046 1272959 1759101 9598276 11641047 14799346 8284600 2940880 2231638 277423 342669 3645774 1860306 1466478 1785468 26649845 30764995 2559101 1779589 11496405 8142390 71060713 66731497 2248874 2214429 256856 87661 12429879 8094356 14935609 10396446 X 12366174 12695578 43758930 43639473 56125104 56335051 71060713 66731497 -2213688 2423635 0 X X 0 1 X 1 0 X ABBOTT NORTHWESTERN HOSPITAL MINNEAPOLIS MN 11498816 13732545 10729875 17801434 7376504 61139174 11498816 13732545 10729875 17801434 7376504 61139174 16381067 44758107 683142 655272 941514 838820 1377795 4496543 65635717 27130900 0.68190 0.59780 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 24265464 182792 2393916 903007 25939165 23720058 4811688 -3433065 833217 24265464 21900155 21827 2568161 770085 23720058 19894833 20000 2720319 734998 21900155 16808398 20000 3776792 710357 19894833 0.00000 0.69954 0.30046 0 0 1724621 732356 992265 1429151 1127950 301201 492002 492002 1785468 RIGHT OF USE ASSET, NET 7975729 PRINCIPAL 457 (F) 166661 8142390 LEASE LIABILITY 8094356 8094356 X 16673789 2423635 2423635 14250154 86313 86313 14336467 16463842 0 16463842 86313 86313 16550155 PART V, LINE 4: THE FOUNDATION'S ENDOWMENT FUNDS ARE USED FOR EDUCATION, CARDIOLOGY RESEARCH, CARDIAC SURGERY RESEARCH AND TO SUPPORT RESEARCH CHAIRS AND PHYSICIAN RESEARCH. PART X, LINE 2: THE FOUNDATION HAS RECEIVED A DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE INDICATING IT IS CLASSIFIED AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C)(3) AND IS NOT A PRIVATE FOUNDATION UNDER SECTIONS 509(A)(1) AND 170(B)(1)(A)(III) OF THE INTERNAL REVENUE CODE. THE FOUNDATION IS ALSO EXEMPT FROM MINNESOTA INCOME TAXES UNDER MINNESOTA STATUTE CHAPTER 290.05. THE FOUNDATION IS SUBJECT TO FEDERAL AND STATE INCOME TAXES ONLY ON ANY UNRELATED BUSINESS INCOME UNDER THE PROVISIONS OF SECTION 511 OF THE INTERNAL REVENUE CODE. THE FOUNDATION FOLLOWS ACCOUNTING STANDARDS FOR UNCERTAIN TAX POSITIONS AND FILES AS A TAX-EXEMPT ORGANIZATION. THE FOUNDATION HAS NO UNCERTAIN INCOME TAX POSITIONS AND NO LIABILITY HAS BEEN RECOGNIZED BY THE FOUNDATION UNDER THIS STANDARD. 1 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPENTS N/A 32808 CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS N/A 1720420 0 0 0 0 0 0 1753228 0 1753228 SUB-SAHARAN AFRICA TO ESTABLISH A RHD TRAINING CENTER 5400 WIRE TRANSFER 0 N/A N/A SUB-SAHARAN AFRICA TO ESTABLISH A RHD TRAINING CENTER 27408 WIRE TRANSFER 0 N/A N/A 0 2 STIPENDS SOUTH ASIA 4 48000 WIRE TRANSFER N/A N/A 0 0 0 0 0 0 PART I, LINE 2: THE FOUNDATION MONITORS THE USE OF THESE INTERNATIONAL GRANTS BY REQUESTING AND RECEIVING SIGNED LETTERS FROM GRANTEE ORGANIZATIONS ATTESTING TO THE APPROPRIATE USE OF THESE FUNDS. ADDITIONAL DUE DILLIGENCE INCLUDES FLLOWING THE GUIDELINES REGARDING BEST PRACTICES PUBLISHED BY THE DEPARTMENT OF THE TREASURY. PART I, LINE 3: THE ACCRUAL METHOD OF ACCOUNTING IS USED TO ACCOUNT FOR EXPENDITURES. HEART 360 CONCERT FOR A CAUSE 942917 405953 536964 69625 169605 408000 242987 WOMEN'S 27657 18831 8826 3000 38111 25174 1 10819 8000 2819 230 457 981393 432784 548609 72625 207946 408000 268618 957189 -408580 1 X X X X 0 1 0 0 0 0 0 0 0 KRISTINE FORTMAN CHIEF EXECUTIVE OFFICER 379022 0 90989 0 258 0 128842 0 0 0 599111 0 90989 0 JESSE HICKS VICE PRESIDENT-ADVANCEMENT 208507 0 50000 0 90 0 48003 0 0 0 306600 0 50000 0 CHARLES ZAUGG CHIEF FINANCIAL OFFICER 180646 0 18155 0 258 0 38219 0 20412 0 257690 0 18155 0 LISA TINDELL VICE PRESIDENT - RESEARCH 178345 0 33810 0 258 0 42588 0 0 0 255001 0 33810 0 TAMARA O'BLACK SENIOR DIRECTOR, QUALITY 176051 0 17300 0 138 0 36436 0 14053 0 243978 0 17300 0 KRISTIN LAMBRECHT PROGRAM DIRECTOR - CIRC 171191 0 17000 0 90 0 40711 0 13567 0 242559 0 17000 0 ROSS GARBERICH VICE PRESIDENT - SCIENTIFIC SERVICES 173984 0 16481 0 54 0 35982 0 14053 0 240554 0 16481 0 JANET DICK CHIEF TALENT AND STRATEGY 177443 0 16904 0 229 0 27042 0 9347 0 230965 0 16904 0 LARISSA STANBERRY DIRECTOR OF DATA SCIENCE 166811 0 16000 0 90 0 25366 0 486 0 208753 0 16000 0 BAVANA RANGAN PROGRAM DIRECTOR - CCAD 162014 0 15605 0 60 0 29472 0 0 0 207151 0 15605 0 PART I, LINE 4B PARTICIPANTS IN A 457(F) PLAN INCLUDE THE FOLLOWING INDIVIDUALS: KRISTINE FORTMAN, CHARLES ZAUGG, TAMARA O'BLACK, JESSE HICKS, ROSS GARBERICH, LISA TINDELL, JANET DICK, AND CINDY RESMAN. TOTAL AMOUNTS CONTRIBUTED TO THE PLAN IN 2023 WERE AS FOLLOWS: KRISTINE FORTMAN: $37,852 CHARLES ZAUGG: $9,441 TAMARA O'BLACK: $9,000 JESSE HICKS: $10,400 ROSS GARBERICH: $8,900 LISA TINDELL: $8,892 JANET DICK: $0 CINDY RESMAN: $17,000 NO FUNDS WERE DISTRIBUTED FROM THE 457(F) PLAN IN 2023. X 9 768100 MARKET VALUE 0 0 1 0 PART I, COLUMN (B): COLUMN (B) REPORTS THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 1A THE FOUNDATION'S EXECUTIVE COMMITTEE CONSISTS OF THE BOARD OFFICERS, CHAIRS OF EACH COMMITTEE OF THE BOARD AND ANY OTHER SUCH MEMBERS AS DIRECTED BY THE CHAIR. THE CHAIR OF THE BOARD SHALL BE THE CHAIR OF THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE HAS ALL THE POWERS OF THE BOARD BETWEEN MEETINGS OF THE BOARD, EXCEPT THAT IT SHALL NOT HAVE THE POWER TO FILL VACANCIES OF ITS OWN MEMBERSHIP NOR VACANCIES IN THE MEMBERSHIP OF THE BOARD OF DIRECTORS, THE POWER TO FILL SUCH VACANCIES BEING VESTED IN THE BOARD. IN ADDITION, UNLESS OTHERWISE DIRECTED BY THE BOARD, THE EXECUTIVE COMMITTEE SHALL FUNCTION AS THE PERSONNEL, FINANCE AND AUDIT COMMITTEES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE FORM 990 IS REVIEWED BY THE FINANCE AND AUDIT COMMITTEE WHO THEN PASSES IT ALONG TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS FOR REVIEW AND APPROVAL. THE FORM 990 IS PROVIDED TO THE BOARD OF DIRECTORS IN ADVANCE OF THE EXECUTIVE MEETING WHERE ACTION IS TAKEN TO APPROVE OR MODIFY THE FORM 990. UPON APPROVAL, THE FORM 990 IS FILED WITH GOVERNMENT AGENCIES. FORM 990, PART VI, SECTION B, LINE 12C ALL BOARD MEMBERS, PHYSICIANS, AND RESEARCH STAFF ARE COVERED BY A CONFLICT OF INTEREST POLICY REQUIRING ANNUAL CONFLICT OF INTEREST DISCLOSURES, AND MAY BE SUBJECT TO CONFLICT MANAGEMENT PLANS (CMPS) AS DETERMINED BY THE APPROPRIATE COI COMMITTEE OR DEPARTMENT. COI DISCLOSURES AND CMPS ARE DOCUMENTED AND HELD CONFIDENTIALLY. IN THE CASE OF BOARD MEMBERS, CMPS MAY INCLUDE EXCLUSION FROM THE PORTION OF ANY MEETING DURING WHICH PROPOSED TRANSACTIONS OR ARRANGEMENTS WITH THE FOUNDATION THAT RAISE ACTUAL OR POTENTIAL CONFLICTS OF INTEREST ARE DISCUSSED. FORM 990, PART VI, SECTION B, LINE 15 A SUBCOMMITTEE OF THE EXECUTIVE COMMITTEE SERVES AS THE COMPENSATION COMMITTEE FOR THE CEO AND EXECUTIVE TEAM (VP OF ADVANCEMENT, MARKETING, AND COMMUNICATIONS; CHIEF TALENT, EDUCATION AND STRATEGY OFFICER; CHIEF FINANCIAL OFFICER; VP, CLINICAL RESEARCH OPERATIONS; SENIOR DIRECTOR, COMPLIANCE, QUALITY & REGULATORY AFFAIRS). EXECUTIVE COMMITTEE OBTAINS COMPARABLE COMPENSATION DATA FROM SURVEYS AND/OR CONSULTANTS TO ASSIST THEM IN THEIR DELIBERATIONS. ALL MEMBERS OF THE EXECUTIVE COMMITTEE ARE INDEPENDENT OF THE CEO AND EXECUTIVE TEAM. THE DELIBERATION AND DECISION PROCESS IS CONTEMPORANEOUSLY SUBSTANTIATED IN THE EXECUTIVE COMMITTEE MEETING MINUTES. THIS PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2023. COMPENSATION PACKAGES FOR THE EXECUTIVE TEAM WERE DETERMINED THROUGH A COMBINATION OF PERFORMANCE REVIEWS, COMPARABILITY DATA FROM AN OUTSIDE CONSULTANT, AND THROUGH DISCUSSIONS WITH THE CHIEF TALENT, EDUCATION AND STRATEGY OFFICER, THE CEO, AND EXECUTIVE COMMITTEE. THIS PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2023. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE AT THE FOUNDATION'S OFFICES. IF REQUESTED, COPIES ARE AVAILABLE BY MAIL. THE AUDITED FINANCIAL STATEMENTS AND ANNUAL REPORT ARE AVAILABLE ON THE FOUNDATION'S WEBSITE. THE FORM 990 AND ALL ACCOMPANYING SCHEDULES ARE AVAILABLE ON-LINE THROUGH GUIDESTAR OR UPON REQUEST. FORM 990, PART IX, LINE 11G RESEARCH STUDY - IRB FEES: PROGRAM SERVICE EXPENSES 151,466. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 151,466. MEDICAL CONSULTING/TESTING FEES: PROGRAM SERVICE EXPENSES 386,435. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 386,435. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 1,031,364. MANAGEMENT AND GENERAL EXPENSES 297,077. FUNDRAISING EXPENSES 73,874. TOTAL EXPENSES 1,402,315. MARKETING CONSULTING: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 190,136. FUNDRAISING EXPENSES 18,201. TOTAL EXPENSES 208,337. FORM 990, PART XII, LINE 2C: THIS PROCESS HAS NOT CHANGED FROM PRIOR YEAR.